Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


  • Manfred Schwab
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_1038-2


Trade name Erbitux® is a chimeric IgG1κ monoclonal antibody specifically binding to epidermal growth factor receptor (EGFR).

Epidermal growth factor receptor (EGFR) (EGFR, ErbB-1, HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands. Ligands which induce activation of EGFR are epidermal growth factor and transforming growth factor-α, for example. Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer. EGFR dimerization stimulates its intrinsic intracellular protein-tyrosine kinase activity resulting in activation of several signal transduction cascades which lead to DNA synthesis and cell proliferation. EGFR mutations can lead to EGFR overexpression or overactivity and consequently result in uncontrolled cell division. Mutations of EGFR have been identified in several types of cancer, such as lung cancer and...


Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Mutation Growth Factor Inhibitor Epidermal Growth Factor Receptor Overexpression Epidermal Growth Factor Family 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

See Also

  1. (2012) Monoclonal antibody therapy. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 2367–2368. doi: 10.1007/978-3-642-16483-5_3823Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.German Cancer Research Center (DKFZ)HeidelbergGermany